xtandi
astellas pharma europe b.v. - enzalutamid - prostata-neoplasmen - endokrine therapie - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
xtandi 40 mg filmtabletten
astellas pharma ag - enzalutamidum - filmtabletten - enzalutamidum 40 mg, hypromellosi acetas succinas, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 3 mg, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (flavum), pro compresso obducto. - prostatakarzinom - synthetika
xtandi 80 mg filmtabletten
astellas pharma ag - enzalutamidum - filmtabletten - enzalutamidum 80 mg, hypromellosi acetas succinas, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 6 mg, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (flavum), pro compresso obducto. - prostatakarzinom - synthetika
xtandi 40 mg weichkapseln
astellas pharma ag - enzalutamidum - weichkapseln - enzalutamidum 40 mg, antiox.: e 320, e 321, excipiens für die kapsel. - prostatakarzinom - synthetika
enzalutamid sandoz 40 mg - filmtabletten
sandoz gmbh - enzalutamid -
enzalutamid sandoz 80 mg - filmtabletten
sandoz gmbh - enzalutamid -